Plasmid DNA Production Global Market Report 2022: Increasing Number of Patients Opting for Gene Therapy as Treatment for Fuel Growth – | So Good News


DUBLIN–(Business Wire)–“The report has been added: “Plasmid DNA Production Market, Global Forecast to 2022-2033, by Stage, Development Level, Application, Disease and Region”. of An offering.

The plasmid DNA manufacturing market size is estimated at USD 525.12 million by 2022 and is expected to witness a CAGR of 13.87% during the forecast period 2023-2033. Rising demand for plasmid (pDNA) DNA; increasing public understanding of cell and gene therapy; Patients’ treatment of choice is contributing to the growth of the market due to the increase in the number of patients opting for gene therapy.

Additionally, high government spending on the healthcare industry and increasing geriatric population are expected to drive market growth. In addition, An increase in partnerships or collaborations among the many organizations involved in this sector underscores the growing interest in plasmid DNA production. However, the high price of gene treatments and potential combinatorial mutagenesis are likely to inhibit growth.

The increasing number of partnerships or collaborations between the many organizations involved in this sector underscores the growing interest in plasmid DNA production. for example, Biotage introduces Biotage PhyPrep, a revolutionary automated plasmid DNA purification solution, in June 2021. Laboratory staff can save time by repeating the same process thanks to a new, largely automated method for plasmid DNA purification. supercoiled The dual flow chromatography technology of PhyTip columns is fully utilized to generate endotoxin-free, transfection-grade pDNA.

As their treatment is predicted to accelerate market growth, the number of patients opting for gene therapy is increasing. Gene therapy is a cutting-edge field of medicine that offers promising new treatments for individuals with a variety of ailments. for example, Intrathecal injection of Adeno-associated AAV2 vectors expressing a therapeutic gene (RPE65) improves vision in individuals with Leber’s Congenital Amaurosis.


Segmentation: Plasmid DNA Manufacturing Market Report 2022 – 2033

level (revenue, million USD); 2022 – 2033

level of development (revenue, million USD); 2022 – 2033

  • Clinical therapy

  • Preclinical Therapeutics

  • Marketing remedies

Application (revenue, million USD); 2022 – 2033

  • Cell and gene therapy

  • Immunotherapy

  • DNA vaccines

  • Others

disease (revenue, million USD); 2022 – 2033

  • Genetic disease

  • Infectious disease

  • Cancer

By region (revenue, US$ million); 2022 – 2033

North America


  • Germany

  • France

  • UK

  • Spain

  • Italy

  • The rest of Europe

Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Rest of APAC

Latin America

  • Brazil

  • Mexico

  • Argentina

  • Rest of LATAM

Middle East and Africa

  • South Africa

  • GCC

  • The rest of the MEA

Key topics include:

1. Research methodology

2. Introduction: Production of Plasmid DNA

3. Executive Summary

4. Market Dynamics

5. Market environment analysis.

6. COVID-19 Impact Analysis: Plasmid DNA Manufacturing Market

7. Level wise market analysis.

8. Market Analysis by Stage of Development.

9. Market analysis by application.

10. Market Analysis by Disease.

11. Regional Market Analysis.

12. North America Plasmid DNA Manufacturing Market

13. Europe Plasmid DNA Manufacturing Market

14. Asia PacificPlasmid DNA Manufacturing Market

15. Latin America Plasmid DNA Production Market

16. MEA Plasmid DNA Manufacturing Market

17. Analysis of Competitor.

18. Company Profiles

19. Conclusion and Recommendations

The companies mentioned.

  • Aldevron

  • Luminous BioSciences LLC

  • VGXI

  • Kaneka Corporation

  • The Cell and Gene Therapy Catapult

  • Charles River Laboratory

  • Natural technology

  • Eurofins Genomics

  • Lonza Inc.

  • Akron Biotech.

For more information on this report, please visit


Source link